Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    Michael Chen, CEO and co-founder, Nuclera
    13 January 2026

    Nuclera extends Series C funding to $87M to advance antibody engineering

    Additional $12M financing led by Elevage Medical Technologies and Jonathan Milner alongside existing investors British Business Bank, and GK GohThe funding will accelerate development of eProtein Discovery for full-format antibody expression, purification, and binding validationCambridg...

    man and women looking at a screen
    12 January 2026

    Why cultural literacy has become an execution skill in life sciences

    In life sciences, execution failures are often explained in familiar terms: regulatory complexity, funding constraints, or technological readiness. Yet in practice, many promising initiatives stall or unravel for a quieter reason — misaligned assumptions between people, professions and ...

    OutSee’s leadership team – James Peach (Left), COO, Dr Julian Gough (Centre), CEO and Founder, and Dr Chang Lu (Right), CSO
    12 January 2026

    OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

    Oversubscribed £2.5M seed round led by Ahren Innovation CapitalStrategic collaboration with o2h to progress drug discovery programmeCambridge, UK, 12 January 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery...

    Steve Smith, CEO, iXCells Biotechnologies
    12 January 2026

    iXCells Biotechnologies appoints Steve Smith as CEO

    Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services ...

    Team consulting partner with London Institute for Healthcare Engineering
    9 January 2026

    Advancing UK MedTech innovation with collaboration - London Institute for Healthcare Engineering partnership with Team Consulting

    Team Consulting is delighted to announce a new collaboration with the London Institute for Healthcare Engineering (LIHE), part of King’s College London. Drawing on our 40-year track record in healthcare innovation, this partnership marks an acceleration in the journey from breakthrough ...

    FairJourney Bio
    12 January 2026

    FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA

    Expanded offering provides high-resolution structural insights to support antibody discovery and biologic designPORTO, Portugal, and SAN DIEGO, USA, 12 January 2026 – FairJourney Bio (FJBio), a leading global provider of antibody discovery and development services, today announced ...

    Rebecca Simmons, PhD, COO, Qureight
    12 January 2026

    Qureight appoints Rebecca Simmons as Chief Operating Officer

    Experienced operational leader across medical research and deep tech appointed to support sustainable growth as part of Qureight’s strategy to scale company operationsCambridge, UK, 12 January 2026 – Qureight, a techbio company advancing the understanding of lung and heart disease throu...

    www.enhancedgenomics.com
    9 January 2026

    Enhanced Genomics appoints Dr Katerina Leftheris to its Board of Directors

    Experienced leader in preclinical and clinical drug development will support expansion of Company’s therapeutics pipeline for complex and common genetic diseases ...

    Why 454 Million People Are Waiting for a Device Already in Their Pocket
    9 January 2026

    Why 454 million people are waiting for a device already in their pocket

    The Smartphone Revolution in Respiratory Care Has Arrived, And It Changes EverythingHere's an uncomfortable truth: we've had the technology to transform respiratory diagnostics for years. It's sitting in your pocket right now. ...

    FairJourney Bio
    8 January 2026

    FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

    PORTO, Portugal, 08 January, 2026 – FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 30
    • Page 31
    • Current page 32
    • Page 33
    • Page 34
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS